Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease

@inproceedings{Butler2015ExomeSO,
  title={Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease},
  author={Timothy M. Butler and Katherine Johnson-Camacho and Myron Peto and Nicholas J. Wang and Tara A. Macey and James Korkola and Theresa M. Koppie and Christopher L . Corless and Joe W. Gray and Paul T. Spellman and Kristy L Richards},
  booktitle={PloS one},
  year={2015}
}
The identification of the molecular drivers of cancer by sequencing is the backbone of precision medicine and the basis of personalized therapy; however, biopsies of primary tumors provide only a snapshot of the evolution of the disease and may miss potential therapeutic targets, especially in the metastatic setting. A liquid biopsy, in the form of cell-free DNA (cfDNA) sequencing, has the potential to capture the inter- and intra-tumoral heterogeneity present in metastatic disease, and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…